This Bull Market Indicator called NVDA at $116

Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…

All you have to do is follow this link here

John Carey Biography and Net Worth

VP of TransMedics Group

Currently, John F. Carey occupies the position of Vice President-Operations of TransMedics Group, Inc. and Vice President-Operations at TransMedics, Inc. (a subsidiary of TransMedics Group, Inc.).

He previously held the position of Vice President-Operations for Vasca, Inc., Principal at Galileo Electro-Optics Corp. and Principal at C. R. Bard, Inc. (New Jersey).

John F. Carey received an undergraduate degree from the University of Massachusetts.

What is John F. Carey's net worth?: The estimated net worth of John F. Carey is at least $1.09 million as of January 17th, 2023. Mr. Carey owns 14,120 shares of TransMedics Group stock worth more than $1,090,064 as of November 21st. This net worth estimate does not reflect any other assets that Mr. Carey may own. Learn More about John F. Carey's net worth.
How do I contact John F. Carey?: The corporate mailing address for Mr. Carey and other TransMedics Group executives is 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810. TransMedics Group can also be reached via phone at (978) 552-0900 and via email at [email protected]. Learn More on John F. Carey's contact information.
Has John F. Carey been buying or selling shares of TransMedics Group?: John F. Carey has not been actively trading shares of TransMedics Group in the last ninety days. Most recently, John F. Carey sold 1,410 shares of the business's stock in a transaction on Tuesday, January 17th. The shares were sold at an average price of $62.71, for a transaction totalling $88,421.10. Following the completion of the sale, the vice president now directly owns 14,120 shares of the company's stock, valued at $885,465.20. Learn More on John F. Carey's trading history.
Who are TransMedics Group's active insiders?: TransMedics Group's insider roster includes John Carey (VP), Nicholas Corcoran (Insider), Laura Damme (VP), Stephen Gordon (CFO), Waleed Hassanein (CEO), Edwin Kania, Jr. (Director), Tamer Khayal (Insider), Miriam Provost (VP), and Anil Ranganath (Insider). Learn More on TransMedics Group's active insiders.
Are insiders buying or selling shares of TransMedics Group?: In the last year, insiders at the sold shares 45 times. They sold a total of 477,855 shares worth more than $53,882,883.25. The most recent insider tranaction occured on November, 5th when Director Edward M Basile sold 6,750 shares worth more than $563,962.50. Insiders at TransMedics Group own 7.0% of the company. Learn More about insider trades at TransMedics Group.
Information on this page was last updated on 11/5/2024.

John F. Carey Insider Trading History at TransMedics Group

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/17/2023	Sell	1,410	$62.71	$88,421.10	14,120
12/2/2022	Sell	10,000	$63.50	$635,000.00	13,808
11/1/2022	Sell	3,000	$49.03	$147,090.00	771
10/3/2022	Sell	3,000	$42.09	$126,270.00	771
8/1/2022	Sell	3,000	$41.27	$123,810.00	771
7/29/2022	Sell	4,000	$40.01	$160,040.00	771
7/20/2022	Sell	1,500	$34.57	$51,855.00	379
7/11/2022	Sell	1,500	$32.98	$49,470.00	379
6/27/2022	Sell	3,320	$32.59	$108,198.80	379
6/24/2022	Sell	2,956	$32.57	$96,276.92	379
6/1/2022	Sell	1,500	$28.19	$42,285.00	379
5/4/2022	Sell	1,500	$25.31	$37,965.00	379
4/1/2022	Sell	1,500	$26.85	$40,275.00	379
3/28/2022	Sell	4,500	$25.01	$112,545.00
11/1/2021	Sell	1,680	$28.16	$47,308.80
10/1/2021	Sell	1,680	$32.33	$54,314.40
9/1/2021	Sell	1,680	$31.98	$53,726.40
7/1/2021	Sell	1,680	$33.65	$56,532.00
5/3/2021	Sell	1,680	$28.34	$47,611.20	702
4/5/2021	Sell	3,360	$36.87	$123,883.20	3,360
3/11/2021	Sell	3,200	$37.50	$120,000.00
9/1/2020	Sell	2,000	$17.59	$35,180.00	5,200
8/3/2020	Sell	2,000	$18.61	$37,220.00	5,200
7/1/2020	Sell	2,000	$17.09	$34,180.00	4,094
6/1/2020	Sell	2,000	$13.21	$26,420.00	5,200
5/1/2020	Sell	2,000	$17.05	$34,100.00	5,200
4/7/2020	Sell	2,000	$13.10	$26,200.00	5,200

John F. Carey Buying and Selling Activity at TransMedics Group

TransMedics Group Company Overview

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Today's Range

Now: $77.20

$75.61

$81.09

50 Day Range

MA: $122.08

$77.20

$165.98

2 Week Range

Now: $77.20

$66.76

$177.37

Volume

2,889,274 shs

Average Volume

2,355,708 shs

Market Capitalization

$2.59 billion

P/E Ratio

82.13

Dividend Yield

N/A

Beta

2.08